[
  {
    "ts": null,
    "headline": "Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication",
    "summary": "FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.",
    "url": "https://finnhub.io/api/news?id=de597e0e5618655dc2f7e202a71d92176b70bb63b59b74ed97301dd74e77f4c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748030520,
      "headline": "Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication",
      "id": 134685841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.",
      "url": "https://finnhub.io/api/news?id=de597e0e5618655dc2f7e202a71d92176b70bb63b59b74ed97301dd74e77f4c0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success",
    "summary": "Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced five-year beneficial survival results for XTANDI combined with ADT therapy. Despite these significant developments, the company's shares rose 2%, in line with broader market movements which showed resilience despite trade tensions revived by President Trump's tariff threats. Given the...",
    "url": "https://finnhub.io/api/news?id=1c0a2b1383c67e5ff4fd8dcd0586a8c4d2d7fefc83166cd4f717a220df9a4a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748021593,
      "headline": "Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success",
      "id": 134685842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced five-year beneficial survival results for XTANDI combined with ADT therapy. Despite these significant developments, the company's shares rose 2%, in line with broader market movements which showed resilience despite trade tensions revived by President Trump's tariff threats. Given the...",
      "url": "https://finnhub.io/api/news?id=1c0a2b1383c67e5ff4fd8dcd0586a8c4d2d7fefc83166cd4f717a220df9a4a0b"
    }
  },
  {
    "ts": null,
    "headline": "The New Covid-19 Jab Policy Wasn’t Up for Debate at the FDA’s Vaccine Meeting. Major Questions Remain.",
    "summary": "The New Covid-19 Jab Policy Wasn’t Up for Debate at the FDA’s Vaccine Meeting. Major Questions Remain.",
    "url": "https://finnhub.io/api/news?id=0b50ea9317de1f7fefa815d65e318f8dc08e0056e95f1cc481e5a364df2fb089",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748006160,
      "headline": "The New Covid-19 Jab Policy Wasn’t Up for Debate at the FDA’s Vaccine Meeting. Major Questions Remain.",
      "id": 134680860,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "The New Covid-19 Jab Policy Wasn’t Up for Debate at the FDA’s Vaccine Meeting. Major Questions Remain.",
      "url": "https://finnhub.io/api/news?id=0b50ea9317de1f7fefa815d65e318f8dc08e0056e95f1cc481e5a364df2fb089"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Should Watch Teva Despite Regional Risks",
    "summary": "Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=cf24b2a0bb360e2a3e02f53e94632fe654e0bd890ffdc8997680f5ed687da4e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748004723,
      "headline": "Why Investors Should Watch Teva Despite Regional Risks",
      "id": 134667049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1206782047/image_1206782047.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=cf24b2a0bb360e2a3e02f53e94632fe654e0bd890ffdc8997680f5ed687da4e5"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More",
    "summary": "NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.",
    "url": "https://finnhub.io/api/news?id=59a3830d496ef3fbade1f1989ca3df3639c5a7edfffa1a4c920c1359c49011d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748002560,
      "headline": "Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More",
      "id": 134660681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.",
      "url": "https://finnhub.io/api/news?id=59a3830d496ef3fbade1f1989ca3df3639c5a7edfffa1a4c920c1359c49011d7"
    }
  },
  {
    "ts": null,
    "headline": "Astellas and Pfizer’s Xtandi combo reduces death risk in prostate cancer trial",
    "summary": "Subjects with high-volume disease experienced a 36-month improvement in median OS.",
    "url": "https://finnhub.io/api/news?id=afb4af559c60af04e7df0ac22c77c812c1ee39f036b69520389b10dc44ba53c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747992684,
      "headline": "Astellas and Pfizer’s Xtandi combo reduces death risk in prostate cancer trial",
      "id": 134658707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Subjects with high-volume disease experienced a 36-month improvement in median OS.",
      "url": "https://finnhub.io/api/news?id=afb4af559c60af04e7df0ac22c77c812c1ee39f036b69520389b10dc44ba53c2"
    }
  },
  {
    "ts": null,
    "headline": "Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2",
    "summary": "Nona Biosciences announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 , a first-in-class mesothelin -targeting...",
    "url": "https://finnhub.io/api/news?id=68e3a40da873014ba49b1c938edc70a0f92765009f48ec6b085fd7431c4c3477",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747963221,
      "headline": "Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2",
      "id": 134655388,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Nona Biosciences announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 , a first-in-class mesothelin -targeting...",
      "url": "https://finnhub.io/api/news?id=68e3a40da873014ba49b1c938edc70a0f92765009f48ec6b085fd7431c4c3477"
    }
  }
]